000			07722nam a2200469 i 4500
999			_c382798 _d382798
001			382798
003			ES-MaUEC
005			20230102122016.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			220518s2022 sz | o |||| 0|eng d
020			_a9783030880712
024	7		_a10.1007/978-3-030-88071-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRA1270.N36 _b2022 EB
245	0	0	_aNanotoxicology in Safety Assessment of Nanomaterials _cedited by Henriqueta Louro, Maria João Silva
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XII, 439 páginas)
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aAdvances in Experimental Medicine and Biology _x2214-8019 _v1357
505	0		_aPart I: Nanotechnologies: Synthesis, application and characterization of nanomaterials -- Chapter 1. Challenges in Nanomaterial Characterization - From Definition to Analysis (José Catita) -- Chapter 2.Trends in the design and evaluation of polymeric nanocarriers: the in vitro nano-bio interactions (Ana Bettencourt, Lídia Gonçalves) -- Chapter 3. LipNanoCar technology - A versatile and scalable technology for the production of lipid nanoparticles (Vera L.R. Esgueira, Clara P.A. Lopes, Ana Catarina A. dos Santos, Fátima C.R.V. Pinto, Silvia A. Sousa, Dragana P.C. de Barros, Jorge H. Leitão, Luis P. Fonseca) -- Chapter 4. Dermal delivery of lipid nanoparticles: Effects on skin and assessment of absorption and safety (Fátima Pinto, Luis P. Fonseca, Dragana P.C. de Barros) -- Chapter 5. Targeting cancer by using nanoparticles to modulate Rho GTPase signalling (Paulo Matos, Joana F. S. Pereira and Peter Jordan) -- Chapter 6. Nanocelluloses: production, characterization and market (Paulo J. T. Ferreira, Ana F. Lourenço) -- Part II: Nanotoxicology: concepts and methodologies for toxicity evaluation of the nanomaterials -- Chapter 7. Nanotoxicology assessment and safety aspects of nanocelluloses for 3D bioprinting applications (Gary Chinga-Carrasco, Jennifer Rosendahl, and Julia Catalán) -- Chapter 8. New "omics" approaches as a tool to explore mechanistic nanotoxicology (Célia Ventura, Vukosava Torres, Luís Vieira, Bruno Gomes, António Sebastião Rodrigues, José Rueff, Deborah Penque, Maria João Silva) -- Chapter 9. Epigenetic mechanisms in understanding nanomaterial-induced toxicity (Manosij Ghosh, Lode Godderis, Peter Hoet) -- Chapter 10. Cellular and molecular mechanisms of toxicity of ingested nanomaterials (Adriana Vieira, Ana Gramacho, Dora Rolo, Nádia Vital, Maria João Silva, Henriqueta Louro) -- Chapter 11. Nanomaterial-induced extra-pulmonary health effects - the importance of next generation physiologically relevant in vitro test systems for the future of nanotoxicology (Ali Kermanizadeh, Gwyndaf Roberts) -- Chapter 12. Drosophila as a suitable in vivo model in the safety assessment of nanomaterials (Eşref Demir, Fatma Turna Demir, and Ricard Marcos) -- Chapter 13. Toxicological aspects of iron oxide nanoparticles (Natalia Fernández-Bertólez,b, Carla Costa, Fátima Brandão, João Paulo Teixeira, Eduardo Pásaro, Vanessa Valdiglesias, Blanca Laffon) -- Chapter 14. Hazard assessment of benchmark metallic nanomaterials through a set of in vitro genotoxicity assays (Nádia Vital, Mariana Pinhão, Naouale El Yamani, Elise Rúden-Pran, Henriqueta Louro, Maria Dušinská, Maria João Silva) -- Part III: Towards the risk assessment and regulation of nanomaterials -- Chapter 15. Nanomaterials, a new challenge in the workplace (Ana Rita Alberto, Cristina Matos, Gabriel Carmona-Aparício, Muriel Iten) -- Chapter 16. Nanomaterials in foods and human digestion: an important layer in the assessment of potential toxic effects (Carla Martins, Paula Alvito, Ricardo Assunção) -- Chapter 17. Adverse Outcome Pathways (AOPs) development, a tool for predictive nanotoxicology (Dora Rolo, Ana Tavares, Nádia Vital, Maria João Silva and Henriqueta Louro).
520			_aSince its advent, nanotechnologies are considered key enabling technologies that take advantage of a wide array of nanomaterials (NMs) for biomedical and industrial applications generating significant societal and economic benefits. However, such innovation increases human exposure to these substances through inhalation, ingestion or dermal contact raising public health concerns. Furthermore, the NMs' specific physicochemical properties, that confer them unique beneficial characteristics, can also elicit nano-bio interactions leading to toxicity and concerns for public health. In addition, such properties can be affected by the surrounding matrix, particularly when incorporated in complex matrices such as food products, leading to secondary features potentially more relevant than primary characteristics for determining their toxicological outcome. These nano specific issues raise the question of whether the NMs may produce adverse outcomes that are not accounted for when using conventional toxicological approaches to assess their safety. Such uncertainties about the safety of NMs for human health and the environment may hamper a faster and more widespread exploration of their potentials. In response, the NMs definition has evolved, and nanotoxicology has developed towards new and more integrative approach methods to support regulatory and policy actions. This book provides a perspective on recent developments in the synthesis, application, and characterization of NMs and the related nanotechnologies, focusing on nanotoxicology for their accurate safety assessment early in the product development stage. The use of complex in vitro models, including multicellular systems and organoids, and "omics-based" approaches, such as transcriptomics or epigenomics, have greatly contributed to an in-depth understanding of the cellular and molecular mechanisms behind some NMs toxicity. Such mechanistic knowledge is equally addressed in this book and has set the basis for a predictive nanotoxicology approach building on adverse outcome pathways. In addition, considering the knowledge provided by the above-mentioned approaches, insights into risk assessment, standardization, and regulation of NMs are also included. Incorporating adequate nanosafety assessment early in the life-cycle of NMs will allow the implementation of the safe and sustainable-by-design paradigm enabling safety to keep pace with innovation. Chapters 10 and 15 are available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
988			_aSpringer_BiomedLife_2022
650		7	_2embne _9158454 _aMateriales nanoestructurados
650		7	_2embne _9140328 _aToxicología
700	1		_aLouro, Henriqueta. _eeditor literario _0(orcid)0000-0001-9744-7332 _1https://orcid.org/0000-0001-9744-7332
700	1		_aSilva, Maria João. _eeditor literario _0(orcid)0000-0002-6060-0716 _1https://orcid.org/0000-0002-6060-0716
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9783030880705
776	0	8	_iPrinted edition: _z9783030880729
776	0	8	_iPrinted edition: _z9783030880736
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-88071-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2022 _dz _eb _zSI